Q4 2022 Science 37 Holdings Inc Earnings Call
Speaker 2: Greetings. Welcome to the Science 37 Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation.
Speaker 2: If anyone should require operator assistance during the conference, please press star zero from your telephone keypad.
Speaker 2: Please note this conference is being recorded. I'll now turn the conference over to Stephen Halper with LifeSci Advisors.
Speaker 3: Steven, you may now begin. Thank you, Rob, and thank you all for participating in today's call. Joining me are David Komen, Chief Executive Officer, and Mike Zarenak, Chief Financial Officer. Earlier today, Science 37 released financial results for the quarter ended December 31st.
Speaker 3: A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.
Speaker 3: These forward-looking statements are based upon our current estimates of various assumptions and involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. We encourage you to review our filings made with the Securities Exchange Commission for discussion of these statements.
Speaker 3: any obligations to update such statements for new information. We believe that certain non-GAAP metrics are useful in evaluating our operational performance. We use these non-GAAP measures to evaluate our ongoing operations and for internal planning and forecasting purposes. Information about non-GAAP financial measures referenced in this slide is not an official
Speaker 3: including a reconciliation of those measures to the most comparable GAAP measures, can be found in our SEC filings and in earnings materials available on the investor relations portion of our website at investors.science37.com. I would now like to turn the call over to David Komen. David.
Speaker 4: Thanks, Steve. Good morning, everyone, and thank you for joining us.
Speaker 4: We're pleased to report fourth quarter results that exceeded our most recent guidance.
Speaker 4: and represent significant improvements quarter over quarter.
Speaker 4: Fourth quarter revenue was $15.9 million, finishing the year at $70.1 million, which was ahead of our expectations.
Speaker 4: Fourth quarter adjusted EBITDA was also ahead of expectation and marked an improvement of more than 20% quarter over quarter from negative 14.6 million to negative 11.6 million, finishing the year at negative 62.5 million.
Speaker 4: We also saw a healthy rebound in bookings in the fourth quarter with gross bookings of $33 million which included a sizable new project win from a repeat customer.
Speaker 4: Our net bookings in the fourth quarter were just under $19 million, which includes the impact from the large scope reduction that we discussed on the third quarter call. As we look forward to 2023, given the previously reported industry challenges, including longer decision making time.
Speaker 4: more cost consciousness and drug funding challenges.
Speaker 4: The 2022 booking shortfall, particularly in the third quarter.
Speaker 4: and project cancellation that we reported throughout the year. We're providing 2023 revenue guidance of $55 to $60 million for the year.
Speaker 4: In response to these challenges, I'd like to take a few moments to highlight the steps we've taken to increase revenue growth and execute on our path to profitability.
Speaker 4: With the addition of our new Chief Commercial Officer, Michael Shipton, who joined us late in the third quarter, we're starting to gain measured optimism for top-line growth acceleration.
Speaker 4: As you may have seen in our recent website update, we have prioritized our metasite offering as it is the greatest area of customer demand and provides us with the greatest differentiation for our company.
Speaker 4: Michael has also hired a new head of inside sales and growth accounts to generate additional demand among new customers.
Speaker 4: in addition to a head of real-world evidence to promote the unique value of our metasite for long-term follow-up.
Speaker 4: He also expanded our CRO network with the most recent edition of Wuxi from China and is deepening our relationships and our strategic accounts.
Speaker 4: We believe all these additions will generate a material return to Bookings growth as we progress throughout 2023.
Speaker 4: We are excited about the continued maturation of our technology infrastructure at the hands of our Chief Technology Officer, Troy Brianton.
Speaker 4: We're particularly excited about the recent purchase of the Volt Health Life Sciences platform which will allow us to accelerate development plans we had underway for workflow features such as advanced scheduling, investigational product tracking, and data exchange with electronic data capture and electronic medical record systems.
Speaker 4: These enhanced capabilities will help us to reduce some of the manual efforts required to execute centralized clinical trials and drive operational efficiencies.
Speaker 4: With cost containment efforts like these and the previously reported headcount reductions announced last quarter, we expect to achieve
Speaker 4: 2023 EBITDA of negative 48 to negative 50 million dollars.
Speaker 4: And we continue to progress toward our objective to reach even to positive.
Speaker 4: cash flow neutral by the end of 2024 without having to raise additional capital.
Speaker 5: We'll be back.
Speaker 4: I'll now turn the call over to Mike Zoranik, our chief financial officer, to provide additional detail regarding our financial performance.
Speaker 4: Thank you, David, and good morning, everyone. I will discuss the fourth quarter results for the period end of December 31st, 2022, and then affirm our outlook for the full year 2023.
Speaker 4: In the fourth quarter, we reported revenues of $15.9 million, which represents a 22% decrease from the same period of the prior year.
Speaker 4: However, it's important to note that if you exclude COVID-related studies from both the fourth quarter 2021 and 2022 periods, our underlying business will continue to expand with fourth quarter revenue growth up 19% year-over-year.www. terryamer emeritus here at the market for sustained income quality. Disotonin Shells and
Speaker 4: As we noted in our fourth quarter earnings release, full year 2022 revenues increased 18% year over year. Again, if COVID related studies were excluded from both the full year 21 and 22 numbers, our revenue growth was up 65% year over year.
Speaker 4: Consistent with our comments on the quarterly 2022 earnings calls, COVID-related studies represented a much smaller percentage of our revenue for full year 2022 and accounted for a very small percentage of our year-end 2022 backlog.
Speaker 4: We finished the fourth quarter with $33 million of gross bookings and just under $19 million of net bookings, which represents a significant increase compared to the third quarter.
Speaker 4: The majority of the difference between the growth and net bookings was related to a final project reconciliation which occurred in the fourth quarter.
Speaker 4: You may recall we mentioned on the third quarter earnings release call we had one study wrap up early Due to customer being able to utilize a lower patient count to prove the trial endpoints
Speaker 3: The final project reconciliation associated with this project was completed in the fourth quarter at which point we took the project realization reduction to backlog.
Speaker 4: Excluding this final reconciliation, actual cancellations during the quarter were insignificant.
Speaker 4: Adjusted gross margin was 24.5% for the fourth quarter compared to 23.2% for the same period last year.
Speaker 4: Adjusted gross profit for the fourth quarter was $3.9 million compared to $4.7 million in the same period of the prior year. I wanted to provide an update on the cost actions we announced on the third quarter earnings call. We remained on track for the cost reduction plan and realized approximately one month of savings of that annual plan in the fourth quarter. Ten general and administrative expenses.
Speaker 4: excluding $5.1 million in stock-based compensation, was $15.5 million in the fourth quarter, a decrease of $3.7 million versus the third quarter of 2022 due to the restructuring program that we implemented, as well as lower variable expenses.
Speaker 4: Additionally, selling general and administrative expenses, excluding stock-based compensation, declined nearly 41% in the fourth quarter of 2022 versus the fourth quarter of 2021.
Speaker 4: Adjust the debits, though, which we calculate by adding back depreciation, amortization, taxes, interest, other income, stock-based compensation, and other non-cash charges, with a loss of $11.6 million in the quarter, representing a $3 million sequential improvement compared to the third quarter of 2022.
Speaker 4: and a $9.9 million improvement, million dollar improvement, first of the fourth quarter of 2021.
Speaker 4: On a four-year basis, our adjusted EBITDA was negative 62.5 million, which exceeded the 2022 adjusted EBITDA guidance we originally provided during the first quarter 2022 earnings with earlier today's call.
Speaker 4: In the fourth quarter, we also took a non-cash impairment of $44 million related to our long-lived assets.
Speaker 4: Given our operating models in the early stages of scale, and the market capitalization of the company was for a sustained period, less than cash in books value, under US gas we were required to perform an analysis regarding the recoverability of long-lifed asset carrying values asset the balance sheet day. Under US gas accounting standards.
Speaker 4: This analysis we performed included an impairment of our long-lived assets was appropriate during the fourth quarter.
Speaker 4: Again, this is a non-cast charge.
Speaker 4: We do not view the impairment necessarily as a reflection of the long-term business benefits of our software-related projects, the life of our platform, both of which remain robust in our ability to deliver for our customers.
Speaker 4: To be clear, we remain confident and laser focused on the future returns on our investments in our unified technology stack, which is further enhanced by the Vault purchase which we announced in the first quarter of 2023.
Speaker 4: And large part due to the $44 million non-cash impairment, US gas net loss.
Speaker 4: with 66.5 million versus a gap net loss of 65.1 million in the fourth quarter a year ago.
Speaker 4: The adjusted net loss for the fourth quarter was $16.9 million, which compared to an adjusted net loss of $23.4 million in the same period last year.
Speaker 4: Additionally, we end at 2022 with $254 million in federal cumulative net operating loss carry forwards.
Speaker 4: Now turning to cash. We ended the quarter with $108.1 million of cash and cash equivalents. In the fourth quarter, our cash burn was approximately $22 million, which included some one-time costs for restructuring and other items of approximately $3 million.
Speaker 4: excluding these one-time items our cash burn improves sequentially quarter over quarter.
Speaker 4: As a reminder, from a modeling standpoint, annual bonuses are paid to qualifying employees in the first quarter, which will impact our first quarter cash burn this year.
Speaker 4: Additionally, concurrent with our earnings release, we filed with the SEC a post-effective amendment and a shell for administration statement.
Speaker 4: The former was required by the registration rights agreement that we entered into as part of the merger agreement from when we went public.
Speaker 4: And we view the shelf registration as a prudent financial management tool.
Speaker 4: Many public companies have an effective shelf registration for this purpose. We became F3 eligible in November of last year and filed the shelf registration this morning.
Speaker 4: As a reminder, if we were to conduct an offering pursuant to this registration statement, we would be required to file a prospective supplement for that transaction.
Speaker 4: Now let's turn to the outlook for 2023.
Speaker 4: In light of the challenging business conditions that we continue to experience, we expect our 2023 revenues to be in the range of $55 million to $60 million for the full year.
Speaker 4: Additionally, we expect adjusted EBITDA for 2023 to be between negative 50 million to negative 48 million.
Speaker 4: As of December 31st, we had approximately 116.1 million shares outstanding.
Speaker 4: As we currently anticipate having a net loss in the upcoming quarter and year, any converted options would be deemed anti-dilutive and therefore, on a GAAP basis, we expect basic and diluted share counts to be the same.
Speaker 4: In summary, we continue to execute for our customers.
Speaker 4: We delivered underlying growth in the business to exclude the COVID study-related revenues and exceeded our most recent guidance for the fourth quarter.
Speaker 4: We remain committed to delivering long-term profitability to create value for shareholders.
Speaker 4: And at this point, I'd like to turn the call back over to David for closing comments.
Speaker 4: I'd like to turn the call back over to David for closing comments. Thank you, Mike.
Speaker 4: While the environment remains challenging and proud of the focus and resiliency we see across our employees and overall stakeholders
Speaker 4: We'll continue to execute on our strategy and deliver value to our customers by driving.
Speaker 4: improvements in our technology and solutions. With that, I'll now turn the call over to the operator and open it up for questions.
Speaker 2: Thank you. At this time, we'll be conducting a question and answer session.
Speaker 2: If you'd like to ask a question today, please press star 1 from your telephone keypad and the confirmation tone will indicate your line is in the question queue.
Speaker 2: You may press star 2 if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys.
Speaker 2: One moment please, and we poll for questions. Thank you.
Speaker 2: Thank you and our first question is from the line of Frank Tackenden with Lake Street Capital Markets. Please assist with your questions.
Speaker 2: Hey, thanks for taking the questions. I wanted to start with one on bookings first. I know in previous calls you've talked about your intentional shift towards pursuing larger contract business. I was curious if any of that was the reason for the strong bookings, and if you could also just provide a broader update on the intentional switch to larger contract business. That would be great too.
Speaker 2: Thanks for calling in. Thanks for the question. We're seeing......
Speaker 4: larger deals in the pipeline as a result of our intentional move toward metasite. We continue to push into that direction. And so we continue to see very large deals. We did close very large deal in the fourth quarter amongst an existing customer, which is terrific.
Speaker 4: We're going to continue to see that. I can't say we're also seeing more traction in what we had announced, I think, two earnings calls ago, but it was the Medisight Lite solution.
Speaker 4: where we're acting as a rescue or risk mitigation strategy, starting small and growing on a performance basis. So that's also getting traction for us.
Speaker 4: With greater intention, we expect to build, continue to build a high quality pipeline, and we expect these efforts to pay off in the long run.
Speaker 2: Okay, that's helpful. And then help me, Bridge, I think I've got the backlog calculation at about $173 million incorporating in the net bookings in this quarter. Help, Bridges, to the guide from $173 million in backlog and how should we be thinking about
Speaker 4: You're absolutely correct, $173 billion in total backlog as of 12-31-22. We expect that to burn over the life of the project.
Speaker 4: Most of them, almost all of them are exclusive.
Speaker 4: Entirely multi-year contracts, some are some long-term follow-up studies, which may extend greater than five to seven years. If you look at the portion of the backlog that we expect to be converted in 2023.
Speaker 4: We're starting off the year with about $49 million of phased backlog for 23, which implies a coverage of 82 to 89% as of the beginning of the year.
Speaker 5: Thank you.
Speaker 2: Our next question is coming from the line of Max Smock with William Blair. Please receive your questions.
Speaker 6: Hi, it's Christine on for MaxMak.
Speaker 6: Just the first one for me, can you give a breakdown of your current sales mix in terms of delivery models, so TechPlus, Metasite, and then full DCP? And is there any notable shift you're seeing one way or another in terms of certain offerings? Thanks.
Speaker 4: I would say that we're being very intentional in our push towards Metasite as we believe that it offers the greatest level of differentiation for the company and we're seeing the greatest amount of demand for it.
Speaker 4: As we continue to move forward, we expect that to continue to be the primary vehicle for both pipeline
Speaker 4: bookings and ultimately backlogs.
Speaker 6: Great. That's really helpful. And then just a couple short ones. What is the sort of implied cadence on the top and bottom line for your 2023 guide? And then if you disclose, can you talk about your renewal rate?
Speaker 6: from existing customers and how this has been trending over the last couple of quarters. Thanks.
Speaker 4: So in terms of the revenue guide, in our current plan, we're expecting more revenues in the second half of 23 versus...
Speaker 4: the first half and just to put some context around that, that's in excess of 25% higher in the second half versus the first half from a revenue perspective.
Speaker 5: Thank you.
Speaker 2: The next question is from the line of Charles Wright with TD Cowen. Please proceed with your questions.
Speaker 7: Yeah, thanks for taking the question. You know, David and Mike, you mentioned David in the prepared comments about some new hires, to help kind of kickstart the sales efforts more. Can you just go over those again? I kind of missed a little bit, but also, you know, below that, what's the mandate for additional hires in the Salesforce?
Speaker 4: The new hires on the commercial front, we brought in a new head of inside sales and growth accounts. We brought in a new head of inside sales and growth accounts.
Speaker 4: and a new head of real-world evidence.
Speaker 4: the inside sales and growth accounts that's being really intentional to identify, generate leads,
Speaker 4: inside sales and growth accounts that's being really intentional to identify, generate leads, and close.
Speaker 4: deals amongst customers that we don't have a relationship with today.
Speaker 4: The head of real-world evidence we brought in I mentioned the earnings call last quarter that I thought that that recognized or that was a good opportunity for us and
Speaker 4: and somewhat untouched. And so with the new head of real world evidence, I think that opens up the door for us for long term follow up studies.
Speaker 4: We think we can close more goals. In regards to existing customers, he's shifted the business development organization to be very active for improving
Speaker 2: specific around mining the current relationships that we have. So that's both amongst us.
Speaker 4: pharma and CRO partners which we continue to want to build relationships with.
Speaker 7: And beyond that, are we, you know, what's the plans for adding to the BizDev team? Like, how many BizDev reps do you have currently? I remember at one point, I think you were sort of in the teams. If you just remind me of like where we're at and, you know, what's in the guides and, you know, obviously you're taking calls down, but.
Speaker 7: what are assumptions for adding to that team as you move through the year now that you have two new heads of groups?
Speaker 8: We don't expect to, you know, We don't expect to, you know,
Speaker 4: expand that team dramatically as the year goes on. I think that we've got
Speaker 4: dramatically as the year goes on, I think that we've got a solid
Speaker 4: team in place, it's really more about taking the people that we do have and organizing them in the right way so we can be very intentional with
Speaker 4: demand generation, identifying new opportunities, mining those opportunities, and solutioning those opportunities ultimately to improve the wind rates that we bring in.
Speaker 4: I think that's the key for us is to ensure that we are solutioning properly to make it clear what we're offering, why Science 37 is differentiated and better, and closing more to you.
Speaker 7: Maybe the last question for Mike. You mentioned to you know remember that in the first quarter bonuses go out for qualified employees. Obviously you're indicating if we're going to model EBITDA loss there's an extra amount in the first quarter but from a revenue perspective any kind of
directional guidance you can provide in terms of how we should think about REV-REC. I know that to an earlier question, but maybe to the cadence that we should think about as we go through at least the first part of the year? Sure, sure, and just a point of clarification. The bonus payout is more cash burn item as opposed to necessarily an EBITDA impact.
In terms of the revenue phasing throughout the year, as I mentioned earlier, we do expect to have more skewing of revenue towards the second half of this year, with the second half of this year being more than $2 billion.
25% higher than the first half.
by percent higher than the first half. That's better than the guidance.
We also expect to see your overall growth in the second half of this year. Our next question is from the line of May. Hewitt with Craig Hell. Please issue your questions. Please issue your questions.
Good morning, thank you for taking the questions. Maybe first up, as you look at the current form of biotech landscape, I think...
There's been a lot of news talking about kind of rationalization of pipelines, reprioritization that happened maybe spring of last year, it obviously happened again in the fall of last year which impacted your Q3 results, but as you talk to your pharma customers, partners now, do you get the sense that that's that we're through that now and it's really about...
from an industry standpoint, longer decision making timelines because they're being a lot more intentional with their
spend a lot more cost pressure that they're feeling is being translated into their discovery efforts. We are seeing funding issues within the biotech space still, so I don't see that changing in the short term. One modeling question regarding gross margins.
excess capacity out of the organization in Q4.
Growth margins will be impacted by revenue. And so from that standpoint, I think that as we have that skewing towards more revenue in the second half of 2023, we have two cuts.
You should see some improvement on the gross margin side. Up until that point, from our modeling perspective, probably not a material change versus where we've been. You're flat out of the gate and then sequentially moving up as the year progresses. Correct.
Thank you very much. Thanks, Matt. Thanks, Matt.
I want to come back to one question from Christine that we were asked earlier, we did not address, regarding the mix between new and existing clients. I think we've said this previously, but want to reemphasize this. At current size and scale, one or two projects can make a material difference in terms of the bookings in a particular quarter. For example...
To David's earlier point, we did win a very large project from a top 10 pharma that was the repeat customer in the fourth quarter of 2022. But if you look at overall throughout the course of 2022, we were able to increase gross bookings from new customers by more than 40%.
And fair to say that if you look at the mix between new and existing customers, for the full year 2022, it was skewed roughly about two-thirds to the new customer front and about a third from existing customers.
So a good mix between the two can vary by quarter, but for the full year, those were risks.
The next question is from the line of Evans-Dover. It was paired. Please receive your questions.
Hey, I've got a few. You've had some big rifts recently. At the same time, you're trying to invest in your sales and your tech headcount as well. I mean, obviously a big change in the stock price, big change in dynamics the last 12 months. But retention, employee retention and satisfaction and kind of...
the areas that are really key and strategic for you and what you're seeing there? I think the key to employee engagement and retention goes back to the fundamental business idea of Science37. There really isn't a company in the clinical trial space that is going to be the key to employee engagement and retention. I think that's the key to employee engagement and retention. I think that's the key to employee engagement and retention.
can is innovative and can provide employees closer
access or proximity to patients themselves. And so many people come to Science 37 because of those two reasons. And we continue to see that as the primary driver for retention for the company.
you know, we have had a few, you know, the RIF that we announced at the end of the year. I think that, you know, that always puts a, put some stress, I think, on the organization. And so, you know, we're being really intentional about putting warm blankets on the employees that are still there and we...
think very highly of them and want to make sure that they understand that they're highly appreciated and so we do things every day to make sure that that's understood.
Okay, fair enough. I mean, it's early on a Monday. I don't know if I missed this, but you guys have been reiterating kind of the...
Long-range runway on EBITDA and cash flow break-evens by the end of 24. I didn't hear that. Is that something that you're stepping away from now? Just curious there.
No, not at all. That's still part of our plan. We still intend to deliver on that.
Fair enough. Final question for me. TRO channel partnerships, obviously you've got several of them, some more important than others, but...
Can you talk to any major shifts, either positively or negatively, amongst those channel partnerships in the last 90, 120 days? I think specifically there was...
any major shifts either positively or negatively amongst those channel partnerships in the last 90, 120 days and I think specifically there was
Sunios out there with a medible partnership renewal and curious if that specifically had or going to have any impact on science 37.
Now we continue to maintain the relationships that we have announced. One of the great things about Michael Shipton as the new head of the commercial organization is that he comes from the CRO space and believes in that channel tremendously and so has invested quite a bit in terms of
I guess re-engineer energizing that channel for us because he believes that that's a great area of expansion and opportunity for us.
All right, that's it for me. Thank you.
Thank you. Thank you. Thank you. At this time, I will turn the floor back over to Stephen Halper for closing remarks.
Thank you, Rob, and thank you, everyone. We look forward to speaking with you next quarter.
Thank you to everyone joining us today. This will conclude today's conference. You may disconnect your lines at this time. Thank you for your participation.